Abstract
The current asthma management guidelines recommend that all but patients with the mildest disease should be treated with a combination of inhaled corticosteroids and β2-agonists, the latter preferably on an as-needed basis. This article reviews the clinical implications of these recommendations, and also examines the potential economic and quality of life (QOL) effect of this therapy.
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call